QUESTION 271
person Asked by .
bookmark_add
Biomarker cystatin C. [10 marks]
description
Clinical Response
"
"
10 Marks
What Is Cystatin C
Cystatin C is a low molecular weight (13 kDa) non-glycosylated cysteine proteinase inhibitor, produced at a constant rate by essentially all nucleated cells in the body. It is freely filtered by the glomerulus, almost completely reabsorbed and catabolised (not secreted back) by the proximal tubule, and is not normally present in significant quantity in urine in health — making its serum level a reliable surrogate marker of glomerular filtration rate (GFR).
Why Cystatin C Is a Superior Renal Biomarker Compared to Creatinine
| Property | Serum Creatinine | Cystatin C |
|---|---|---|
| Source | Muscle metabolism (creatine breakdown) | Produced at constant rate by all nucleated cells |
| Dependence on muscle mass | YES – significantly affects level (low in malnourished/low muscle mass children, falsely reassuring GFR) | Largely independent of muscle mass, sex, and age beyond infancy — more reliable across body compositions |
| Sensitivity to early GFR decline | ""Creatinine-blind"" range – can remain normal despite significant GFR loss (up to 50%) due to tubular secretion compensating | Detects early/mild reductions in GFR earlier than creatinine, minimal ""blind"" range |
| Effect of diet/nutritional status | Affected by dietary protein/muscle catabolism | Relatively unaffected by diet |
| Use in neonates/young infants | Confounded by maternal creatinine in the first days of life and low, evolving muscle mass | Less affected by maternal levels beyond the immediate neonatal period; useful adjunct in this population |
Clinical Applications in Paediatrics
- Early detection of acute kidney injury (AKI) – serum and urinary cystatin C rise earlier than creatinine after a renal insult (e.g., post-cardiac surgery, sepsis, nephrotoxic drug exposure), supporting its use as an early AKI biomarker alongside others such as NGAL (neutrophil gelatinase-associated lipocalin)
- More accurate GFR estimation in children with reduced muscle mass – e.g., children with chronic illness, malnutrition, neuromuscular disease, or on chronic corticosteroids, where creatinine-based formulae (Schwartz equation) may overestimate true GFR
- Combined creatinine-cystatin C equations (e.g., the CKiD U25/""bedside Schwartz"" refinements incorporating cystatin C) improve GFR estimation accuracy across the paediatric age range compared to creatinine-only formulae, now increasingly recommended in chronic kidney disease (CKD) staging and monitoring in children
- Research/emerging use as a marker of cardiovascular risk and in monitoring nephrotoxicity from chemotherapeutic and other drugs in children
- Not affected by tubular secretion, making it a more consistent early marker in conditions with reduced GFR but preserved tubular function
Limitations
- Higher assay cost and less widespread availability compared to creatinine
- Levels can be altered by thyroid dysfunction, high-dose corticosteroid therapy, and active inflammation/malignancy, requiring cautious interpretation in these settings
- Reference ranges in very young infants are still being refined compared to the well-established creatinine-based Schwartz equation
🌟 Examiner's Pearls
- Cystatin C production is essentially independent of muscle mass, unlike creatinine — this is the single most important reason it outperforms creatinine in malnourished or low-muscle-mass children.
- It rises earlier than creatinine after an acute renal insult, making it valuable for EARLY AKI detection (e.g., post cardiac-surgery AKI).
- Combined creatinine + cystatin C-based GFR estimating equations (e.g., CKiD U25) are now preferred over creatinine-alone formulae for more accurate paediatric CKD staging.
- It is not a marker of a specific disease but a marker of GFR/renal function — interpret cautiously in the presence of thyroid dysfunction, high-dose steroids, or active malignancy/inflammation, which can independently alter levels.
References: Nelson Textbook of Pediatrics, Chapter on Assessment of Renal Function; Schwartz GJ et al. CKiD Study – New Equations to Estimate GFR in Children, JASN 2009 and CKiD U25 update, JASN 2021; Filler G et al. Cystatin C as a Marker of GFR, Clin Biochem; Ghai Essential Pediatrics, Chapter on Renal Disease.